Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NAP-WORK
NCT05955729Completed
- Sponsor
- CHU Saint-Etienne
- Start
- Feb 2024
- Primary completion
- Sep 2025
- Countries
- 1
01
Overview
Randomised, open-label trial (2 arms), sponsored by CHU Saint-Etienne. Primary endpoint: Reactive Hyperemia Index at 12 weeks. Started Feb 2024; status: completed.
Beyond the preview
Go deeper on NCT05955729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05955729.